Understanding how BAG3 expression and function intersect with genetic determinants of MASLD could thus uncover additional biomarkers and therapeutic targets useful in improving disease stratification and intervention. The gene discussed is BAG3; the disease is metabolic dysfunction-associated steatotic liver disease.